Table 3.
Unadjusted hazard ratios (HRs) for primary and composite endpoints.
| Baseline variable | Units of increase | Renal progression (event/total = 82/331) |
All-cause mortality (event/total = 31/331) |
Composite endpoint (event/total = 100/331) |
|||
|---|---|---|---|---|---|---|---|
| Unadjusted HR (95% CI) |
p | Unadjusted HR (95% CI) |
p | Unadjusted HR (95% CI) |
p | ||
| Age | 1 year | 1.005 (0.988–1.022) | .575 | 1.103 (1.060–1.148) | <.001 | 0.990 (0.974–1.007) | .258 |
| Male vs. female | – | 0.728 (0.471–1.125) | .153 | 1.613 (0.759–3.426) | .213 | 0.700 (0.469–1.046) | .082 |
| Body mass index | 1 Kg/m2 | 1.013 (0.954–1.076) | .666 | 0.855 (0.760–0.962) | .009 | 0.981 (0.923–1.043) | .548 |
| NSAID usage (yes vs. no) | – | 0.580 (0.231–1.455) | .246 | 0.491 (0.066–3.667) | .488 | 0.813 (0.191–3.471) | .780 |
| Chinese herb usage (yes vs. no) | – | 1.095 (0.522–2.297) | .810 | 1.949 (0.663–5.731) | .226 | 1.083 (0.557–2.104) | .814 |
| Use of ACEI/ARB (yes vs. no) | – | 1.214 (0.555–2.655) | .627 | 0.713 (0.178–2.860) | .633 | 0.481(0.166–1.388) | .176 |
| Diabetes (yes vs. no) | – | 6.155 (3.819–9.921) | <.001 | 1.871 (0.917–3.821) | .085 | 2.773 (1.822–4.221) | <.001 |
| hypertension (yes vs. no) | – | 2.541(1.466–4.406) | .001 | 1.186 (0.567–2.482) | .650 | 1.196 (0.736–1.944) | .470 |
| eGFR | 1 mL/min/1.73 m2 | 0.965 (0.955–0.975) | <.001 | 0.979 (0.966–0.991) | .001 | 0.986 (0.976–0.997) | .013 |
| Hemoglobin | 1 g/dL | 0.845 (0.744–0.960) | .010 | 0.894 (0.699–1.144) | .374 | 0.855 (0.752–0.971) | .016 |
| Albumin | 1 g/dL | 0.511 (0.324–0.806) | .004 | 0.597 (0.263–1.352) | .216 | 0.445 (0.275–0.719) | .001 |
| hs-CRP | 1 mg/L | 1.000 (0.983–1.018) | .964 | 1.017 (1.007–1.027) | .001 | 1.014(1.002–1.026) | .022 |
| Ca | 1 mg/dL | 0.374 (0.199–0.702) | .002 | 1.082 (0.478–2.448) | .850 | 0.423 (0.236–0.758) | .004 |
| P | 1 mg/dL | 2.985 (1.903–4.683) | <.001 | 0.856 (0.368–1.991) | .718 | 2.143 (1.385–3.316) | .001 |
| Ca × P | 1 mg2/dL2 | 1.057 (1.015–1.101) | .008 | 0.981 (0.932–1.033) | .465 | 1.022 (0.986–1.059) | .230 |
| Uric acid | 1 mg/dL | 1.207 (1.095–1.329) | <.001 | 1.303 (1.127–1.507) | <.001 | 1.314 (1.152–1.499) | <.001 |
| Systolic blood pressure | 1 mmHg | 1.021 (1.017–1.025) | <.001 | 1.006 (0.999–1.012) | .095 | 1.014 (1.009–1.018) | <.001 |
| Diastolic blood pressure, mmHg | 1 mmHg | 1.017 (0.999–1.015) | .109 | 0.956 (0.943–0.969) | <.001 | 0.979 (0.970–0.988) | <.001 |
| Proteinuria | g/day | 1.445 (1.344–1.554) | <.001 | 1.264 (1.082–1.477) | .003 | 1.290 (1.13–1.472) | <.001 |
| Chronic MS pain (yes vs. no) | – | 1.004 (0.649–1.555) | .984 | 1.045 (0.515–2.120) | .903 | 1.054 (0.710–1.565) | .774 |
Composite endpoint was defined as renal progression or all-cause mortality.
NSAID: nonsteroidal anti-inflammatory drug; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blockage; eGFR: estimated glomerular filtration rate; hs-CRP: high sensitive-C reactive protein; Ca: calcium; P: phosphate; Ca × P: the product of calcium and phosphate; MS: musculoskeletal; BMI: body mass index.